KR20150036553A - 알칼리화제를 함유하지 않는 라퀴니모드 제형 - Google Patents

알칼리화제를 함유하지 않는 라퀴니모드 제형 Download PDF

Info

Publication number
KR20150036553A
KR20150036553A KR1020157003693A KR20157003693A KR20150036553A KR 20150036553 A KR20150036553 A KR 20150036553A KR 1020157003693 A KR1020157003693 A KR 1020157003693A KR 20157003693 A KR20157003693 A KR 20157003693A KR 20150036553 A KR20150036553 A KR 20150036553A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
stable pharmaceutical
mode
filler
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020157003693A
Other languages
English (en)
Korean (ko)
Inventor
가디 사르파티
이오아나 로빈저
다니트 리흐트
무함마드 사파디
Original Assignee
테바 파마슈티컬 인더스트리즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 테바 파마슈티컬 인더스트리즈 리미티드 filed Critical 테바 파마슈티컬 인더스트리즈 리미티드
Publication of KR20150036553A publication Critical patent/KR20150036553A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020157003693A 2012-07-11 2013-07-10 알칼리화제를 함유하지 않는 라퀴니모드 제형 Withdrawn KR20150036553A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261670268P 2012-07-11 2012-07-11
US61/670,268 2012-07-11
PCT/US2013/049894 WO2014011750A1 (en) 2012-07-11 2013-07-10 Laquinimod formulations without alkalizing agent

Publications (1)

Publication Number Publication Date
KR20150036553A true KR20150036553A (ko) 2015-04-07

Family

ID=49914501

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157003693A Withdrawn KR20150036553A (ko) 2012-07-11 2013-07-10 알칼리화제를 함유하지 않는 라퀴니모드 제형

Country Status (19)

Country Link
US (1) US20140018386A1 (https=)
EP (1) EP2872141A4 (https=)
JP (1) JP2015527321A (https=)
KR (1) KR20150036553A (https=)
CN (1) CN104470519A (https=)
AR (1) AR091706A1 (https=)
AU (1) AU2013290274A1 (https=)
BR (1) BR112015000321A2 (https=)
CA (1) CA2873230A1 (https=)
EA (1) EA201590193A1 (https=)
HK (1) HK1209054A1 (https=)
IL (1) IL236229A0 (https=)
MX (1) MX2015000398A (https=)
NZ (1) NZ630241A (https=)
SG (2) SG10201700198VA (https=)
TW (1) TW201408299A (https=)
UA (1) UA115555C2 (https=)
WO (1) WO2014011750A1 (https=)
ZA (1) ZA201500287B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2445451T3 (es) 2007-12-20 2014-03-03 Teva Pharmaceutical Industries, Ltd. Preparaciones estables de laquinimod
CN106063787A (zh) 2012-02-03 2016-11-02 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
JP2015535287A (ja) 2012-11-07 2015-12-10 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドのアミン塩
NZ630427A (en) 2013-03-14 2017-06-30 Teva Pharma Crystals of laquinimod sodium and improved process for the manufacture thereof
EA201692180A1 (ru) 2014-04-29 2017-08-31 Тева Фармасьютикал Индастриз Лтд. Лахинимод для лечения пациентов с рецидивирующе-ремиттирующим рассеянным склерозом (рррс) с высоким статусом инвалидизации
CN107823168A (zh) * 2017-10-25 2018-03-23 北京素维生物科技有限公司 一种快速溶解的片剂及其制备方法
CN107823150A (zh) * 2017-10-25 2018-03-23 北京素维生物科技有限公司 一种可快速分散的片剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
SE0400235D0 (sv) * 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
US7884208B2 (en) * 2005-10-19 2011-02-08 Teva Pharmaceutical Industries, Ltd. Crystals of laquinimod sodium, and process for the manufacture thereof
RS52169B (sr) * 2006-06-12 2012-08-31 Teva Pharmaceutical Industries Limited Stabilni preparati lakvinimoda
ES2445451T3 (es) * 2007-12-20 2014-03-03 Teva Pharmaceutical Industries, Ltd. Preparaciones estables de laquinimod
WO2010070449A2 (en) * 2008-12-17 2010-06-24 Actavis Group Ptc Ehf Highly pure laquinimod or a pharmaceutically acceptable salt thereof
WO2013016686A1 (en) * 2011-07-28 2013-01-31 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and interferon-beta

Also Published As

Publication number Publication date
NZ630241A (en) 2017-09-29
ZA201500287B (en) 2016-10-26
EA201590193A1 (ru) 2015-04-30
TW201408299A (zh) 2014-03-01
IL236229A0 (en) 2015-01-29
US20140018386A1 (en) 2014-01-16
EP2872141A4 (en) 2016-01-13
BR112015000321A2 (pt) 2017-06-27
SG11201407688QA (en) 2014-12-30
WO2014011750A1 (en) 2014-01-16
JP2015527321A (ja) 2015-09-17
EP2872141A1 (en) 2015-05-20
HK1209054A1 (zh) 2016-03-24
AR091706A1 (es) 2015-02-25
WO2014011750A8 (en) 2014-12-04
MX2015000398A (es) 2015-04-10
SG10201700198VA (en) 2017-02-27
AU2013290274A1 (en) 2014-11-27
UA115555C2 (uk) 2017-11-27
CN104470519A (zh) 2015-03-25
CA2873230A1 (en) 2014-01-16

Similar Documents

Publication Publication Date Title
KR20150036553A (ko) 알칼리화제를 함유하지 않는 라퀴니모드 제형
KR100866720B1 (ko) 항치매 약물의 안정화 방법
ES2708955T3 (es) Formulaciones orales de deferasirox
JP2006514052A (ja) 吸湿性および／または潮解性の薬剤を含む固体分散剤
CN110087632A (zh) 乳酸钙组合物和使用方法
US20070110803A1 (en) Pharmaceutical formulation comprising levothyroxine sodium
US20180064669A1 (en) Compositions and methods of providing thyroid hormone or analogs thereof
AU2013250251B2 (en) Encapsulated formulation
SA08290417B1 (ar) تركيبة دوائية ثابتة تشمل ملح فينفلونين القابل للذوبان فى الماء
US20160143855A1 (en) Stable pharmaceutical compositions of thyroid hormone drug
EP4164616A1 (en) Oral formulation comprising a crystalline form of rabeximod
HU225779B1 (en) Pharmaceutical composition containing paracetamol and drotaverine and process for producing it
ES2465998T3 (es) Formulaciones de comprimidos de prasugrel
AU2020204558A1 (en) Compositions and methods of providing thyroid hormone or analogs thereof
WO2016084099A1 (en) Soft gelatin capsule composition of anti-tussive agents
JPH10226644A (ja) 医薬組成物
WO2019094292A1 (en) Compositions and methods of providing thyroid hormone of analogs thereof
CN109195609A (zh) 包含环磷酰胺和卡培他滨的片剂包片剂药物组合物
WO2007049626A1 (ja) カベルゴリン含有経口固形製剤
KR20240173178A (ko) 안정성 및 용출률이 개선된 크리스데살라진 함유 약학 조성물
KR20150056827A (ko) 용출성 및/또는 흡수성이 개선된 경구 투여용 의약 조성물
EP3452077A1 (en) Compositions and methods of providing thyroid hormone or analogs thereof
AU2002241960A1 (en) Process for preparing non-hygroscopic sodium valproate composition
HK1055260A1 (en) Stabilization of solid thyroid drug formulations
HK1206989B (en) Encapsulated formulation

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid
P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000